ScienceDex / Researcher record
Margie L. Clapper
- Fox Chase Cancer Center (no department on record)
From the FY2024 NIH awards this investigator leads as contact PI. The department is the award's.
- Program Leader
- R01 Holder
- Early Career
- Diverse Portfolio
NIH Funding · FY2024
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2024 | $1,641,877 | 5 | #7,524 |
| 2025 | $1,124,184 | 3 | #14,603 |
| 2026 | $4,868,855 | 3 | #2,947 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY2024 · selected5 records
- FY20253 records
- FY20263 records
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 1885626Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2027.
FY2024 award records by amount
NIH award records listing Margie L. Clapper as a PI. Multi-PI records show the full award amount for context.
- 5R01CA262551-03R01Contact PIFolic Acid Supplementation and Colitis-associated Colon Carcinogenesis$525.7Kaward amount
- 75N91019D00022-P00001-759102200001-2N01Contact PIBASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIA$515.6Kaward amount
- 5U54CA272686-03U54Contact PICancer Prevention-Interception Targeted Agent Discovery Program at Fox Chase Cancer Center$397.1Kaward amount
- 3U54CA272686-03S1U54Contact PINovel small molecule agents to correct pathogenic VHL missense mutations$200Kaward amount
- 75N91024D00003-0-759102400001-1N01Contact PITO Title: Contract Orientation & Kickoff Meeting for Preclinical Services for PREVENT Base IDIQ Title: PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate E$3.5Kaward amount
Award organization
Organizations that administered FY2024 awards listing Margie L. Clapper as a PI.
FY2024 award administered by Fox Chase Cancer Center (PA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardFox Chase Cancer Center
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #7524
- 2025$2M Cumulative Funding
- 2025R01 Grant Holder
- 2025Program/Center Grant Leader
- 2026$5M Cumulative Funding
- 2026Entered Top 25% NationallyRanked #2947
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Margie L. Clapper.